retatrutide and heart A concern with a new obesity drug? #retatrutide #elililly retatrutide heart palpitations We have

TripleHormone-Receptor agonist Retatrutide for Obesity A phase 2 trial

A separate double-blind study assessed exenatide's effect on intracranial pressure in women with idiopathic intracranial hypertension [93]

But while getting them is common an estimated 75% of adults get them according to the National Institute of Diabetes and Digestive and Kidney Diseases its important to not neglect them and understand when medical attention is necessary

Retatrutide is a novel once-weekly triple agonist for the GLP-1R, GIPR, and GCGR receptors, showing a stronger action on the human GIP receptor, and exerting weaker effects on the GLP-1 and glucagon receptors

Previously, oral semaglutide (known by the brand name Rybelsus) was FDA-approved only for the treatment of Type 2 diabetes